NCT01288716

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Seaside Therapeutics, Inc. · Industry
• Sex: All
• Age: 5 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in subjects with autism spectrum disorders

Conditions

• Autism Spectrum Disorders

Interventions

Type	Name	Description
DRUG	Arbaclofen

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-08-01
• Completion: 2012-09-01
• First posted: 2011-02-02
• Last updated: 2013-07-31

Locations

24 sites across 1 country: United States